Transport of Pseudomonas aeruginosa in Polymer Solutions

Bacteria often live surrounded by polymer solutions, such as in animal respiratory, gastrointestinal, and reproductive tracts. In these systems, polymer solutions are often exposed to fluid flow, and their complex rheology can affect the transport of chemical compounds and microorganisms. Recent studies have focused on the effect of polymer solutions on the motility of bacteria in the absence of fluid flow. However, flow can be a game-changer on bacterial transport, as demonstrated by the depletion of motile bacteria from the low-shear regions and trapping in the high-shear regions in simple fluids, even for flows as simple as the Poiseuille one. Despite the relevance of polymer solutions in many bacterial habitats, the effect of their complex rheology on shear-induced trapping and bacterial transport in flow has remained unexplored. Using microfluidic experiments and numerical modeling, we studied how the shear rate and the rheological behavior of Newtonian and non-Newtonian polymer solutions affect the transport of motile, wild-type Pseudomonas aeruginosa in a Poiseuille flow. Our results show that, in Newtonian solutions, an increase in viscosity reduces bacterial depletion in the low-shear regions at the microchannel center, due to a reduction in the bacterial swimming velocity. Conversely, in the non-Newtonian solution, we observed a depletion comparable to the buffer case, despite its zero-shear viscosity being two orders of magnitude higher. In both cases, bacterial swimming and polymer fluid rheology control the magnitude of bacterial depletion and its shear-rate dependence. Our observations underscore the importance of the rheological behavior of the carrier fluid in controlling bacterial transport, in particular, close to surfaces giving rise to velocity gradients, with potential consequences on surface colonization and biofilm formation in many naturally relevant microbial habitats

Robust estimation of bacterial cell count from optical density

Optical density (OD) is widely used to estimate the density of cells in liquid culture, but cannot be compared between instruments without a standardized calibration protocol and is challenging to relate to actual cell count. We address this with an interlaboratory study comparing three simple, low-cost, and highly accessible OD calibration protocols across 244 laboratories, applied to eight strains of constitutive GFP-expressing E. coli. Based on our results, we recommend calibrating OD to estimated cell count using serial dilution of silica microspheres, which produces highly precise calibration (95.5% of residuals <1.2-fold), is easily assessed for quality control, also assesses instrument effective linear range, and can be combined with fluorescence calibration to obtain units of Molecules of Equivalent Fluorescein (MEFL) per cell, allowing direct comparison and data fusion with flow cytometry measurements: in our study, fluorescence per cell measurements showed only a 1.07-fold mean difference between plate reader and flow cytometry data

Transport of Pseudomonas aeruginosa in Polymer Solutions

Bacteria often live surrounded by polymer solutions, such as in animal respiratory, gastrointestinal, and reproductive tracts. In these systems, polymer solutions are often exposed to fluid flow, and their complex rheology can affect the transport of chemical compounds and microorganisms. Recent studies have focused on the effect of polymer solutions on the motility of bacteria in the absence of fluid flow. However, flow can be a game-changer on bacterial transport, as demonstrated by the depletion of motile bacteria from the low-shear regions and trapping in the high-shear regions in simple fluids, even for flows as simple as the Poiseuille one. Despite the relevance of polymer solutions in many bacterial habitats, the effect of their complex rheology on shear-induced trapping and bacterial transport in flow has remained unexplored. Using microfluidic experiments and numerical modeling, we studied how the shear rate and the rheological behavior of Newtonian and non-Newtonian polymer solutions affect the transport of motile, wild-type Pseudomonas aeruginosa in a Poiseuille flow. Our results show that, in Newtonian solutions, an increase in viscosity reduces bacterial depletion in the low-shear regions at the microchannel center, due to a reduction in the bacterial swimming velocity. Conversely, in the non-Newtonian solution, we observed a depletion comparable to the buffer case, despite its zero-shear viscosity being two orders of magnitude higher. In both cases, bacterial swimming and polymer fluid rheology control the magnitude of bacterial depletion and its shear-rate dependence. Our observations underscore the importance of the rheological behavior of the carrier fluid in controlling bacterial transport, in particular, close to surfaces giving rise to velocity gradients, with potential consequences on surface colonization and biofilm formation in many naturally relevant microbial habitats.ISSN:2296-424

The Current Status and Future Prospects of KAGRA, the Large-Scale Cryogenic Gravitational Wave Telescope Built in the Kamioka Underground

International audienceKAGRA is a gravitational-wave (GW) detector constructed in Japan with two unique key features: It was constructed underground, and the test-mass mirrors are cooled to cryogenic temperatures. These features are not included in other kilometer-scale detectors but will be adopted in future detectors such as the Einstein Telescope. KAGRA performed its first joint observation run with GEO600 in 2020. In this observation, the sensitivity of KAGRA to GWs was inferior to that of other kilometer-scale detectors such as LIGO and Virgo. However, further upgrades to the detector are ongoing to reach the sensitivity for detecting GWs in the next observation run, which is scheduled for 2022. In this article, the current situation, sensitivity, and future perspectives are reviewed.</jats:p

A global metagenomic map of urban microbiomes and antimicrobial resistance

We present a global atlas of 4,728 metagenomic samples from mass-transit systems in 60 cities over 3 years, representing the first systematic, worldwide catalog of the urban microbial ecosystem. This atlas provides an annotated, geospatial profile of microbial strains, functional characteristics, antimicrobial resistance (AMR) markers, and genetic elements, including 10,928 viruses, 1,302 bacteria, 2 archaea, and 838,532 CRISPR arrays not found in reference databases. We identified 4,246 known species of urban microorganisms and a consistent set of 31 species found in 97% of samples that were distinct from human commensal organisms. Profiles of AMR genes varied widely in type and density across cities. Cities showed distinct microbial taxonomic signatures that were driven by climate and geographic differences. These results constitute a high-resolution global metagenomic atlas that enables discovery of organisms and genes, highlights potential public health and forensic applications, and provides a culture-independent view of AMR burden in cities.Funding: the Tri-I Program in Computational Biology and Medicine (CBM) funded by NIH grant 1T32GM083937; GitHub; Philip Blood and the Extreme Science and Engineering Discovery Environment (XSEDE), supported by NSF grant number ACI-1548562 and NSF award number ACI-1445606; NASA (NNX14AH50G, NNX17AB26G), the NIH (R01AI151059, R25EB020393, R21AI129851, R35GM138152, U01DA053941); STARR Foundation (I13- 0052); LLS (MCL7001-18, LLS 9238-16, LLS-MCL7001-18); the NSF (1840275); the Bill and Melinda Gates Foundation (OPP1151054); the Alfred P. Sloan Foundation (G-2015-13964); Swiss National Science Foundation grant number 407540_167331; NIH award number UL1TR000457; the US Department of Energy Joint Genome Institute under contract number DE-AC02-05CH11231; the National Energy Research Scientific Computing Center, supported by the Office of Science of the US Department of Energy; Stockholm Health Authority grant SLL 20160933; the Institut Pasteur Korea; an NRF Korea grant (NRF-2014K1A4A7A01074645, 2017M3A9G6068246); the CONICYT Fondecyt Iniciación grants 11140666 and 11160905; Keio University Funds for Individual Research; funds from the Yamagata prefectural government and the city of Tsuruoka; JSPS KAKENHI grant number 20K10436; the bilateral AT-UA collaboration fund (WTZ:UA 02/2019; Ministry of Education and Science of Ukraine, UA:M/84-2019, M/126-2020); Kyiv Academic Univeristy; Ministry of Education and Science of Ukraine project numbers 0118U100290 and 0120U101734; Centro de Excelencia Severo Ochoa 2013–2017; the CERCA Programme / Generalitat de Catalunya; the CRG-Novartis-Africa mobility program 2016; research funds from National Cheng Kung University and the Ministry of Science and Technology; Taiwan (MOST grant number 106-2321-B-006-016); we thank all the volunteers who made sampling NYC possible, Minciencias (project no. 639677758300), CNPq (EDN - 309973/2015-5), the Open Research Fund of Key Laboratory of Advanced Theory and Application in Statistics and Data Science – MOE, ECNU, the Research Grants Council of Hong Kong through project 11215017, National Key RD Project of China (2018YFE0201603), and Shanghai Municipal Science and Technology Major Project (2017SHZDZX01) (L.S.

Empagliflozin in Patients with Chronic Kidney Disease

Background The effects of empagliflozin in patients with chronic kidney disease who are at risk for disease progression are not well understood. The EMPA-KIDNEY trial was designed to assess the effects of treatment with empagliflozin in a broad range of such patients. Methods We enrolled patients with chronic kidney disease who had an estimated glomerular filtration rate (eGFR) of at least 20 but less than 45 ml per minute per 1.73 m(2) of body-surface area, or who had an eGFR of at least 45 but less than 90 ml per minute per 1.73 m(2) with a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of at least 200. Patients were randomly assigned to receive empagliflozin (10 mg once daily) or matching placebo. The primary outcome was a composite of progression of kidney disease (defined as end-stage kidney disease, a sustained decrease in eGFR to &lt; 10 ml per minute per 1.73 m(2), a sustained decrease in eGFR of &amp; GE;40% from baseline, or death from renal causes) or death from cardiovascular causes. Results A total of 6609 patients underwent randomization. During a median of 2.0 years of follow-up, progression of kidney disease or death from cardiovascular causes occurred in 432 of 3304 patients (13.1%) in the empagliflozin group and in 558 of 3305 patients (16.9%) in the placebo group (hazard ratio, 0.72; 95% confidence interval [CI], 0.64 to 0.82; P &lt; 0.001). Results were consistent among patients with or without diabetes and across subgroups defined according to eGFR ranges. The rate of hospitalization from any cause was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.86; 95% CI, 0.78 to 0.95; P=0.003), but there were no significant between-group differences with respect to the composite outcome of hospitalization for heart failure or death from cardiovascular causes (which occurred in 4.0% in the empagliflozin group and 4.6% in the placebo group) or death from any cause (in 4.5% and 5.1%, respectively). The rates of serious adverse events were similar in the two groups. Conclusions Among a wide range of patients with chronic kidney disease who were at risk for disease progression, empagliflozin therapy led to a lower risk of progression of kidney disease or death from cardiovascular causes than placebo